Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0242-6498(07)73914-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Diagnosis of pediatric melanocytic tumors].
Dermatologie (Heidelb)
January 2025
Universitäts-Hautklinik Tübingen, Liebermeisterstr. 25, 72076, Tübingen, Deutschland.
The histological diagnosis of pediatric melanocytic tumors is challenging, as benign nevi often resemble aggressive tumors. Accurate diagnosis is crucial for the early detection of rare pediatric melanomas. Recent advancements have established a classification based on genetic backgrounds.
View Article and Find Full Text PDFClear cell variant of calcifying epithelial odontogenic tumour (Pindborg tumour) of the mandible.
BMJ Case Rep
January 2025
Department of Oral and Maxillofacial Surgery, Indira Gandhi Institute of Dental Sciences, Sri Balaji Vidyapeeth (Deemed to be University), Pondicherry, India.
A calcifying epithelial odontogenic tumour (CEOT) is a rare benign odontogenic tumour of epithelial origin accounting for approximately 1% of all odontogenic tumours. The intraosseous form occurs more commonly in the posterior mandible whereas the extraosseous form is common in the anterior maxilla. CEOT is often asymptomatic and presents with a painless swelling of the mandible.
View Article and Find Full Text PDFProspective Validation of CAR-HEMATOTOX and a simplified version predict Survival in Patients with Large B-Cell Lymphoma treated with anti-CD19 CAR T-cells: data from CART-SIE study.
Transplant Cell Ther
January 2025
Chair of Hematology, University of Milan; Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano.
Background: Anti-CD19 CAR T-cells have revolutionized outcomes in relapsed/refractory large B-cell lymphomas. Long-term follow-up underscored the role of hematological toxicity in non-relapse mortality, largely driven by infections, leading to the development of the CAR-HEMATOTOX (HT) score for predicting neutropenia. The European scientific community (EHA/EBMT) later reached a consensus, defining a new entity: immune effector cell-associated hematotoxicity (ICAHT).
View Article and Find Full Text PDFThe Cell Cycle Regulatory Proteins p16, CDK4, and PTEN Are Unsuitable as Biomarkers in Oral Melanocytic Lesions.
J Oral Pathol Med
January 2025
Division of Oral and Maxillofacial Pathology, School of Dentistry, University of São Paulo, São Paulo, São Paulo, Brazil.
Background: Melanocytic neoplasms are rare in the oral cavity and represent a diagnostic challenge due to the overlap between benign and malignant lesions. However, their pathogenesis is not fully elucidated. The aim of this study was to evaluate the expression of the cell cycle-related proteins p16, CDK4, and PTEN in oral melanocytic nevi and melanomas.
View Article and Find Full Text PDFFacile integration of a binary nano-prodrug with αPD-L1 as a translatable technology for potent immunotherapy of TNBC.
Acta Biomater
January 2025
Hengyang Medical School, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, MOE Key Lab of Rare Pediatric Disease, University of South China, Hengyang 421001, China. Electronic address:
Immune checkpoint blockers (ICBs)-based immunotherapy is a favorable approach for efficient triple-negative breast cancer (TNBC) treatment. However, the therapeutic efficacy of ICBs is greatly compromised by immunosuppressive tumor microenvironments (TMEs) and low expression levels of programmed cell death ligand-1 (PD-L1). Herein, we constructed an amphiphilic prodrug by linking a hydrophobic STING agonist, MSA-2 and a hydrophilic chemotherapeutic drug, gemcitabine (GEM) via an ester bond, which can self-assemble into GEM-MSA-2 (G-M) nanoparticles (NPs) with a tumor growth inhibition (TGI) value of 87.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!